Anti-RSV F Glycoprotein [11-3-A3] | Ximbio 151853 product information

product summary

company name :

Ximbio

product type :

antibody

product name :

Anti-RSV F Glycoprotein [11-3-A3]

catalog :

151853

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

861

reactivity :

human

application :

western blot, ELISA, immunocytochemistry

more info or order :

Ximbio product webpage

product information

Name :

Anti-RSV F Glycoprotein [11-3-A3]

Catalogue Number :

151853

Applications :

ELISA IF Fn WB

Antigen/Gene or Protein Targets :

Human Respiratory Syncytial (RS) virus Fusion protein.

Synonyms :

VGP48, VGP70

Reactivity :

Virus

Relevance :

Human Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness and is the chief cause of hospitalization for respiratory tract illness in young children.The glycoprotein F is located on the surface of viral envelope, its function is to induce fusion of viral envelope with host-cell envelope resulting in syncytium formation. The glycoprotein F (also named VP70, F0 or fusion protein) consists of two components: F1 (also named VPG48) and F2 (also named VGP26) held together by disulphide bonds. The reported molecular weight of the VGP26 component varies between 20 to 26 kd.

Host :

Mouse

Immunogen :

Gradient-purified RSF-44 virus (subgroup A) UV inactivated for 20 minutes at 20C

Subclass :

IgG1 kappa

Positive Control :

Immunoblot: (see Figure) Indirect immunofluorescence: staining of RSA-2 infected BSC-1 cells

Myeloma Used :

P3X63Ag8

Recommended Growing Conditions :

Dulbecco’s media containing 20% Fetal Bovine serum (DH20) prepared as follows (for final volume of 300ml: 237ml DMEM plus 60 ml Fetal Bovine Serum plus 3ml L-Glutamine).

Strain :

Balb/c

Research Area :

Virology

Notes :

This antibody has a high neutralising activity; 90% plaque neutralization titre of 103 (Gimenez et al., 1996). This property makes it potentially useful for the preparation of reagents for prevention and/or for therapeutic use in managing RS virus infections (for example, vaccines or new–generation man-made antibodies). This antibody reacts with the fusion protein F (also named VP70 or F0 protein) and specifically to a subunit of the F protein, F1 (also named 48kDa). The antibody reacts with the RS virus F1 protein from both subgroups A and B of the virus. New-generation man-made antibodies, based on the 11-3-A3 antibody, could complement the effectiveness of polivizumab (Synagis), which is used to prevent but not treat established RS virus infections (Nature Biotechnology, 2013: 31, 952). Significantly, there was no evidence of antibody dependant enhancement of RS virus infection in vitro for the 11-3-A3 antibody. The enhancing activity was found for other antibodies to the F protein (Gimenez et al 1996).

more info or order :

Ximbio product webpage